Spectrum Pharmaceuticals to Expand Study of Superficial Bladder Cancer Drug
Complete Response in First Patient Treated Leads Company to Expand the Number
of Clinical Sites and Accelerate Enrollment
IRVINE, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) announced today that it plans to expand the clinical study of Neoquin in superficial bladder cancer, based on a complete response seen in the first patient treated in the study. The patient received six treatments with Neoquin over a period of six weeks, which resulted in the complete disappearance of the tumor. The response was confirmed by biopsy.
"We are pleased to see a complete response in the first patient treated in this study, and it gives us the confidence to expand and accelerate the clinical development of Neoquin," stated Luigi Lenaz, MD, President of the oncology division of Spectrum Pharmaceuticals. "This study was initiated based on peer-reviewed findings by researchers at the University of Bradford reported in the British Journal of Cancer last year, and now we have support for these findings in the first patient treated. We plan to expand the study to at least four sites to increase the speed for enrolling the targeted 20 to 25 patients for the study."
The Company is hosting a conference call today, Wednesday, December 11th at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to provide an update on progress in the implementation of its strategy and plans and objectives going forward. To access the call please dial 888-348-7538 approximately ten minutes prior to the scheduled start time. A replay of the call will be available on our website at www.spectrumpharm.com.
Spectrum Pharmaceuticals develops in-licensed drugs for the treatment and supportive care of cancer patients. The Company's lead drug, satraplatin, is a phase 3 oral, anti-cancer drug. Elsamitrucin, a phase 2 drug, will initially target non-Hodgkin's lymphoma. Neoquin is being studied in the treatment of superficial bladder cancer, and may have applications as a radiation sensitizer. The Company also has a pipeline of pre-clinical neurological drug candidates for disorders such as attention-deficit hyperactivity disorder, schizophrenia, mild cognitive impairment and pain, which it is actively seeking to out-license or co-develop. For additional information visit the Company's web site at www.spectrumpharm.com.
This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
For further information, please contact:
(949) 788-6700, ext. 247